AstraZeneca's Brilinta faces another six month wait at FDA
This article was originally published in Scrip
Potential US approval of AstraZeneca’s ticagrelor (Brilinta) has been pushed back to the summer after the FDA categorised the company’s recent response as a class 2 resubmission. This gives a six-month review cycle and a new PDUFA date of 20 July.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.